Markets:

Overview

News

Currencies

International

Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

864.02 +19.52 (+2.31%)

Streaming Delayed Price Updated: 2:00 PM EDT, Aug 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

16 17 Next >

Micron To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

November 29, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

November 28, 2023

Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering.

Via Benzinga

Why Is Dutch Pharma Argenx Trading Lower Today? ↗

November 28, 2023

Tuesday, Argenx SE (NASDAQ: ARGX) released topline results from the ADVANCE-SC study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with primary immune thrombocytopenia...

Via Benzinga

These 2 Stocks Are Falling in a Fading Rally ↗

November 28, 2023

It's been a good month, but the stock market's looking tired.

Via The Motley Fool

$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗

November 15, 2023

Via Benzinga

$1000 Invested In This Stock 5 Years Ago Would Be Worth $5,000 Today ↗

November 01, 2023

Via Benzinga

Earnings Outlook For argenx ↗

October 30, 2023

Via Benzinga

Argenx Stock Crashes On An Unexpected Failure For Its Biggest Drug ↗

November 28, 2023

The company was hoping its drug would make a difference for patients with a rare blood disorder.

Via Investor's Business Daily

Why SpringWorks Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗

November 28, 2023

Shares of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) surged in pre-market trading after the company reported the FDA approval of OGSIVEO (nirogacestat) as the first and only treatment for adults...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

November 28, 2023

It's time to dive into the biggest pre-market stock movers for Tuesday morning with all of the latest news you need to know today!

Via InvestorPlace

Zscaler Posts Q1 Results, Joins argenx, Cool Company And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

November 28, 2023

U.S. stock futures traded mixed this morning, with the Dow Jones futures gaining around 15 points on Tuesday.

Via Benzinga

Topics Stocks

Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗

October 19, 2023

Via Benzinga

Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗

October 03, 2023

Via Benzinga

argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia

November 28, 2023

From argenx SE

Via GlobeNewswire

Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst ↗

November 22, 2023

Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the

Via Benzinga

argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis

November 16, 2023

From argenx SE

Via GlobeNewswire

Tech Titans Rising: 7 Underrated Stocks Set for Explosive Growth ↗

November 06, 2023

Are you looking to invest in rising tech stocks? Here are seven underrated stocks set for explosive growth.

Via InvestorPlace

Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review ↗

November 03, 2023

Bulls are back in control as the major indexes confirmed the uptrend this week.

Via Investor's Business Daily

argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions

November 01, 2023

From argenx SE

Via GlobeNewswire

argenx to Present at Upcoming Investor Conferences

November 01, 2023

From argenx SE

Via GlobeNewswire

Argenx Comes Up With Big Sales Beat, Narrower-Than-Expected Losses ↗

October 31, 2023

The company sells Vyvgart, a treatment for generalized myasthenia gravis.

Via Investor's Business Daily

Topics Earnings

argenx Reports Third Quarter 2023 Financial Results and Provides Business Update

October 31, 2023

From argenx SE

Via GlobeNewswire

argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023

October 24, 2023

From argenx SE

Via GlobeNewswire

Stock Market Rally Attempt Underway; Micron, Nike, Amazon, Meta In Focus: Weekly Review ↗

September 29, 2023

But it's not a confirmed uptrend yet. Nike, Amazon and Meta were in focus.

Via Investor's Business Daily

What's Going On Pfizer's Subsidiary Biohaven Stock? ↗

September 27, 2023

Pfizer Inc's (NYSE: PFE) subsidiary Biohaven Ltd (NYSE: BHVN) released an

Via Benzinga

Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29% ↗

September 27, 2023

The companies hope by lowering immunoglobulin G, an antibody, that they can treat myriad autoimmune diseases.

Via Investor's Business Daily

Why Immunovant Stock Is Bolting Higher Today ↗

September 27, 2023

The company may have best-in-class autoimmune disease therapy under its roof.

Via The Motley Fool

Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering ↗

September 27, 2023

Both companies are working on drugs that lower an antibody tied to numerous autoimmune conditions.

Via Investor's Business Daily

Immunovant Soars 73% — And Slugs Argenx — As Autoimmune Disease Battle Heats Up ↗

September 26, 2023

Immunovant is hoping to come up with the best drug in its class, lowering a key antibody tied to autoimmune diseases.

Via Investor's Business Daily

Argenx's 28% Surge & Promising Product Propel Investor Confidence

September 25, 2023

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

Via MarketBeat

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

argenx SE - American Depositary Shares (NQ:ARGX)

All News about argenx SE - American Depositary Shares

Starting at /week.